EFSA Tolerable Upper Intake Level for Vitamin B6 in Adults
The EFSA established a tolerable upper intake level (UL) of 12 mg/day for vitamin B6 in adults, including pregnant and lactating women 1.
Key Details of the UL Determination
The EFSA Panel on Nutrition, Novel Foods and Food Allergens conducted a comprehensive scientific opinion in 2023 specifically addressing vitamin B6 upper limits 1. This represents the most current and authoritative guidance on this topic.
Critical Effect and Rationale
- Peripheral neuropathy was identified as the critical adverse effect from excess vitamin B6 intake
- The Panel identified a reference point of 50 mg/day from a case-control study, supported by case reports and vigilance data
- An uncertainty factor of 4 was applied to account for:
- The inverse relationship between dose and time to onset of symptoms
- Limited available data on the precise LOAEL (lowest-observed-adverse-effect-level)
- This calculation (50 mg ÷ 4) yielded 12.5 mg/day, which was rounded to 12 mg/day 1
Age-Specific ULs
The adult UL was scaled down for younger populations using allometric scaling (body weight^0.75) 1:
- Infants (4-11 months): 2.2-2.5 mg/day
- Children (1-6 years): 3.2-4.5 mg/day
- Children/Adolescents (7-17 years): 6.1-10.7 mg/day
- Adults (≥18 years): 12 mg/day
Important Clinical Caveats
Lower-Dose Toxicity Concerns
Recent evidence challenges the assumption that only mega-doses cause toxicity. A 2023 case report documented peripheral neuropathy in a patient taking only 6 mg/day from a multivitamin—half the established UL—with elevated serum B6 levels of 259.9 nmol/L 2. This highlights that:
- Individual susceptibility varies considerably
- The UL represents a population-level safety threshold, not an absolute guarantee of safety for all individuals
- Patients developing neurological symptoms should have vitamin B6 intake assessed even at "low" supplemental doses
Comparison to Other Guidelines
The 2022 ESPEN guideline cites older reference values with higher ULs 3:
- Ages 14-18 years: 80 mg/day
- Ages 19-70+ years: 100 mg/day
These older values are superseded by the 2023 EFSA assessment, which used more rigorous systematic review methodology and incorporated more recent safety data showing toxicity at lower doses 1.
Population Risk Assessment
Based on available intake data, EU populations are unlikely to exceed the 12 mg/day UL from diet alone. The primary risk group is regular users of food supplements containing high doses of vitamin B6 1.
Practical Recommendations
- Review all sources of vitamin B6 in patients taking supplements (multivitamins, B-complex, individual B6 supplements)
- For patients developing peripheral neuropathy, obtain detailed supplement history and consider serum B6 measurement
- The washout period for complete vitamin B6 clearance is 20-40 days based on pharmacokinetic parameters 4
- Advise against routine supplementation above the recommended dietary allowance (1.3-1.7 mg/day for adults) unless clinically indicated 3